TAAR1 and schizophrenia: Further preclinical studies, including the comparison of the pharmacodynamic effects of compound 62 to those of the most advanced TAAR1 agonists as well as classical antipsychotics, are necessary to evaluate the efficacy, safety, and tolerability of this potent and efficacious TAAR1 agonist for the potential development of this compound as a new pharmacotherapy option for schizophrenia and other psychiatric disorders.